Skip to main content
. Author manuscript; available in PMC: 2017 Jun 13.
Published in final edited form as: JAMA Oncol. 2016 Apr;2(4):471–480. doi: 10.1001/jamaoncol.2015.4955

Figure 3. Prognostic Performance of the DDR Pathway Signature.

Figure 3

Kaplan-Meier analysis of the DDR pathway signature for biochemical recurrence-free survival (A and B), metastasis-free survival (C and D), and overall survival (E and F) in the training cohort (A, C, and E) and the pooled validation cohorts (B, D, and F). Kaplan-Meier log-rank test results are shown. Patients at risk in each risk group are shown below each graph. BCR indicates biochemical recurrence.